alexa Glypican-3 expression is silenced in human breast cancer.


Journal of Glycobiology

Author(s): Xiang YY, Ladeda V, Filmus J

Abstract Share this page

Abstract Glypican-3 (GPC3) is a membrane-bound heparan sulfate proteoglycan that is mutated in the Simpson-Golabi-Behmel syndrome. This is an X-linked condition characterized by overgrowth, and various visceral and skeletal dysmorphisms. The phenotype of the Simpson-Golabi-Behmel syndrome patients and GPC3-deficient mice, as well as gene transfection experiments indicate that GPC3 can act as an inhibitor of cell proliferation and survival. It has been previously shown that GPC3 expression is downregulated in mesotheliomas and ovarian cancer. Here we report that GPC3 expression is also silenced in human breast cancer, and that this silencing is due, at least in part, to hypermethylation of the GPC3 promoter. Ectopic expression of GPC3 inhibited growth in eight out of 10 breast cancer cell lines. Collectively, these data suggest that GPC3 can act as a negative regulator of breast cancer growth. This article was published in Oncogene and referenced in Journal of Glycobiology

Relevant Expert PPTs

Recommended Conferences

  • International Conference on Glycobiology
    Sep 21-22, 2017, Crowne Plaza Houston River Oaks, Houston, USA
  • 2nd International Conference on Biochemistry
    Sep 21-22, 2017 Macau, Hong Kong
  • International Conference on Glycobiology
    Oct 02-04, 2017 Atlanta, USA
  • 4th International Conference on Glycobiology and Glycochemistry
    July 16-18, 2018 Melbourne, Australia
  • 4th Glycobiology World Congress
    September 17-19, 2018 Rome, Italy
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version